Bristol Myers Squibb’s Zenbexus Delivers Major Blood Cancer Win, Cuts Progression Risk 51%
Bristol Myers Squibb reports positive Phase 3 trial data, showing ZENBEXUS cuts the multiple myeloma progression risk by 51%.
Stocks · News reference
Cantor Fitzgerald Maintains Neutral on Bristol-Myers Squibb, Lowers Price Target to $53
Cantor Fitzgerald analyst Carter Gould maintains Bristol-Myers Squibb (NYSE:BMY) with a Neutral and lowers the price target from $59 to $53.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors
Aardvark Therapeutics appointed David Zhang, Ph.D., MBA, as an independent board director, bringing over 25 years of clinical development and regulatory expertise from companies including MyoKardia, Genentech/Roche, Alumis, and Abivax. Zhang will support Aardvark's regulatory strategy for ARD-101, its lead candidate for Prader-Willi Syndrome treatment, at a critical juncture following an FDA clinical hold.
Bristol Myers Squibb Says Zenbexus Combo Shows 51% Lower Risk Of Myeloma Progression Or Death vs. Standard Of Care In Phase 3